PMOS Treatment for Complex Cases: How We Care for PMOS Alongside Hashimoto’s, Prediabetes, and Infertility

Medically reviewed by Dr. Alicia McCubbins, ND · Naturopathic Medicine & Functional Fertility

In our last post, we covered the renaming of PCOS to Polyendocrine Metabolic Ovarian Syndrome (PMOS) and what the change means for diagnosis. Part 1: PCOS Is Now PMOS Read that first if you want the clinical and historical context. This post is different. This one is about what PMOS treatment actually looks like when PMOS is not the only condition a patient is carrying.

We treat a lot of women with complex clinical pictures. PMOS rarely arrives alone. It often shows up alongside thyroid disease, autoimmune conditions, insulin resistance moving toward prediabetes, and fertility issues that have been written off by multiple specialists. What follows is a case that brings all of those layers together — and a walkthrough of how we treated each one without losing the thread connecting them.

What is PMOS? A Brief Recap

PMOS, or Polyendocrine Metabolic Ovarian Syndrome, is the new official name for what was previously called Polycystic Ovary Syndrome (PCOS). The Endocrine Society announced the rename on May 12, 2026, following 14 years of global collaboration and the participation of more than 50 patient and professional organizations. The condition affects 1 in 8 women — more than 170 million worldwide.

The rename matters because the new name reflects the actual mechanism. PMOS is a hormonal and metabolic condition, not a condition defined by ovarian cysts. Insulin resistance, hyperandrogenism, and broader metabolic dysregulation are the drivers. The ovarian findings are downstream. For the full clinical context and what a proper PMOS workup involves, see Part 1 of this series.

When PMOS Doesn’t Come Alone: Common Comorbidities

She came to Vytal at 36, carrying four diagnoses and one unanswered question.

The diagnoses:

PMOS, undiagnosed but clinically obvious in retrospect — cycles that had been irregular since adolescence, weight that resisted every standard intervention, recurrent cystic acne, hair changes
Hashimoto’s thyroiditis, diagnosed in her late twenties, managed with levothyroxine but never optimized
Rheumatoid arthritis, diagnosed two years before she found us, controlled on a biologic but with flares she could not predict
Prediabetes, confirmed on her most recent annual physical, with a recommendation to “lose 10 pounds and recheck in six months”

The unanswered question: four years of unexplained secondary infertility. She and her partner had conceived their first child without difficulty in her early thirties. The second was not happening, and no one had been able to tell her why.

Three rheumatologists, an endocrinologist, two reproductive specialists, and her primary care provider had each treated one of her diagnoses in isolation. None of them had treated the system underneath. None had connected her autoimmune burden, her thyroid function, her insulin resistance, and her infertility into a single picture. By the time she found us, she had stopped expecting anyone to.

This is one of the most common patterns we see in PMOS care. PMOS, Hashimoto’s, rheumatoid arthritis, and prediabetes are not random co-occurrences. They share underlying mechanisms — chronic inflammation, insulin dysregulation, and immune dysfunction — and they reinforce each other when treated separately.

PMOS Diagnosis: The Labs and Tools That Matter

Her workup at Vytal looked different from anything she had been given before because it was built around the assumption that her conditions were related, not separate.

The comprehensive PMOS lab panel included:

The metabolic layer — fasting insulin, HOMA-IR, an oral glucose tolerance test with insulin levels, HbA1c
The hormonal layer — free testosterone, DHEA-S, SHBG, the LH-to-FSH ratio, AMH for ovarian reserve, comprehensive sex hormones
The thyroid layer — TSH, Free T3, Free T4, reverse T3, and the autoimmune markers (TPO and thyroglobulin antibodies) that had been used to diagnose her Hashimoto’s but never re-evaluated since
The autoimmune and inflammatory layer — hs-CRP, ESR, ANA, and a deeper look at the inflammatory environment driving both her RA and her metabolic picture
The cardiometabolic layer — ApoB, the triglyceride-to-HDL ratio, lipid subfractions
Nutrient status — vitamin D, ferritin, B12, magnesium, and a methylation panel
A continuous glucose monitor (CGM), worn for two weeks, to give us a real-time read on how her body was actually responding to food

The CGM was the piece her previous providers had not considered, and the piece that ended up changing her plan the most. Her fasting glucose looked acceptable on standard panels. Her real-time data told a very different story — significant post-meal spikes after foods she had considered “safe,” dramatic glucose drops in the late afternoon, and patterns that explained her energy crashes, her cravings, and the slow drift of her HbA1c into the prediabetic range.

How PMOS, Hashimoto’s, and Prediabetes Connect

Her labs told one coherent story instead of four separate ones.

Her PMOS was driving the hyperandrogenism, the irregular cycles, and the insulin resistance — and the insulin resistance was driving the prediabetes. Her Hashimoto’s was undermanaged in ways her TSH alone had been hiding. Her Free T3 was suboptimal. Her reverse T3 was elevated. Her antibodies were still active. Suboptimal thyroid function was contributing to her fatigue, her weight resistance, and the difficulty her body was having sustaining a pregnancy. Her rheumatoid arthritis lived inside the same inflammatory environment that was worsening her PMOS and her insulin resistance, which meant her three “separate” conditions were actively reinforcing one another. Her infertility was the downstream outcome of all of it.

The picture was complex but not chaotic. Once we had the right data, the order of operations became clear.

Our PMOS Treatment Plan: Four Foundational Levers

Her treatment plan was built across the four foundational levers we use for every PMOS patient, with each one tuned to her specific comorbidities.

Nutrition, calibrated by her CGM. Instead of giving her general guidance, we used her continuous glucose data to identify the specific foods and meal structures her body was responding to poorly. Her plan ended up protein-and-fiber-forward with a strict no-naked-carbohydrate rule, a structured afternoon snack to prevent the late-day crash, and an anti-inflammatory pattern to support her autoimmune load. No elimination diet. No tracking apps. Real-time feedback from her own body.
Movement structured for metabolic and joint health. Resistance training three times a week, carefully sequenced around her RA flares. We avoided the high-impact cardio that had been worsening her joint inflammation and replaced it with strength work that simultaneously improved her insulin sensitivity and protected her joints.
Sleep and stress regulation as inflammation management. Her sleep had been fragmented for years. We treated her sleep with the same clinical seriousness as her other conditions, because for a patient with both autoimmunity and insulin resistance, sleep is one of the highest-leverage interventions available. Magnesium glycinate, a consistent wind-down, screen boundaries, and a real conversation about the stress patterns her job and her infertility journey were creating.
Supplementation, targeted not scattered. Inositol for ovarian function and insulin sensitivity. NAC for inflammation, androgen support, and broader antioxidant load. Omega-3s at therapeutic doses for both autoimmune and metabolic benefit. Vitamin D corrected to optimal range. A methylated B-complex. Selenium and zinc, both relevant for thyroid function. Each one had a specific job tied to a specific lab finding.

Medication, layered in strategically. Her levothyroxine dose was adjusted, with the addition of low-dose T3 to address her conversion issue. A short course of compounded GLP-1 therapy to reverse her prediabetes and break the insulin resistance cycle that was driving her PMOS. Spironolactone for the androgen-driven symptoms. We coordinated closely with her rheumatologist on her biologic. The GLP-1 was used as a metabolic intervention with a clear timeline — to bring her insulin resistance down and her HbA1c back into a healthy range before active conception attempts, not as an indefinite treatment.

PMOS Treatment Outcomes: What Changed in 12 Months

Twelve months in, her clinical picture was unrecognizable from where she had started.

Her fasting insulin had dropped substantially. Her HOMA-IR was back in optimal range.
Her HbA1c had moved out of the prediabetic range and into the middle of normal.
Her CGM data, when we repeated it, showed stable glucose patterns through the day and no late-afternoon crashes.
Her thyroid panel was optimized for the first time — Free T3 in range, reverse T3 normalized, antibodies trending down.
Her RA flares had decreased in both frequency and severity, in coordination with her rheumatologist.
Her cycles regulated for the first time in years. Not just “more regular.” Predictable.
And earlier this year, she had a baby.

The pregnancy was the outcome no specialist had been able to deliver in four years of trying. It was not the result of any single intervention. It was the result of treating her conditions as a connected system and giving her body the metabolic and hormonal environment it needed to do what it was capable of doing all along.

PMOS Long-Term Management: Why Ongoing Care Matters

She is still our patient. She will continue to be our patient. PMOS, Hashimoto’s, and RA are not conditions you cure and walk away from. They are conditions you stay in relationship with.

She has the same physician she started with. He has now seen her labs across more than a dozen rounds and can read them in context — what was elevated at intake, what shifted first, what changed during pregnancy, what is stabilizing post-partum. That kind of longitudinal read is not something a new provider can replicate. It is what makes a treatment plan responsive to the patient in front of it instead of generic to the diagnosis.

We run her labs every three to four months. The full panel happens twice a year, with focused interim checks on the markers that matter most for where she is at any given moment. Right now, post-baby, those are her thyroid panel, her fasting insulin, and her inflammatory markers. The cadence does two things at once. It tells us, in real numbers, whether her plan is still working. And it tells her, in real numbers, that her body is responding. For a woman who spent years being told her labs were fine while her body told her something different, watching the numbers move is its own form of trust-building.

PMOS is not curable in the sense that it disappears and never returns. Neither are her autoimmune conditions. They are chronic, metabolic, and inflammatory, which means they live in the relationship between her body, her habits, and the clinical care wrapped around her. With the right framework in place — the right labs run, the right plan built, the right physician in her corner across years — most women in her situation can move from significant symptoms to a place where their conditions are well-managed and no longer running their lives. That is exactly where she is.

If you recognize yourself in any of this, you don’t have to keep doing it alone.

Frequently Asked Questions About PMOS

What is PMOS?

PMOS stands for Polyendocrine Metabolic Ovarian Syndrome. It is the new official name for what was previously called Polycystic Ovary Syndrome (PCOS), renamed by the Endocrine Society in May 2026 to reflect the condition’s metabolic and hormonal nature. PMOS is a chronic endocrine disorder that affects approximately 1 in 8 women, or more than 170 million women worldwide.

Is PMOS the same as PCOS?

Yes. PMOS is simply the new name for PCOS. The medical condition itself has not changed — only its name and the diagnostic framework around it. The rename was driven by research showing that the condition is primarily metabolic and hormonal rather than defined by ovarian cysts.

Can you get pregnant with PMOS?

Yes. Many women with PMOS can conceive, particularly when underlying insulin resistance, hormonal imbalances, and inflammation are addressed. PMOS is one of the most common causes of treatable infertility, and proper PMOS treatment often restores regular cycles and fertility. Outcomes vary by individual, and a comprehensive workup is essential to identify what is specifically driving infertility in any given case.

What labs are used to diagnose PMOS?

A comprehensive PMOS workup looks across three layers: metabolic (fasting insulin, HOMA-IR, oral glucose tolerance test, HbA1c), hormonal (free testosterone, DHEA-S, SHBG, LH-to-FSH ratio), and cardiometabolic (ApoB, triglyceride-to-HDL ratio, hs-CRP). A continuous glucose monitor (CGM) can add real-time insight into how the body responds to food. See Part 1 of this series for the complete diagnostic framework.

Can PMOS occur with Hashimoto’s or other autoimmune conditions?

Yes, and it commonly does. PMOS frequently presents alongside thyroid disorders (especially Hashimoto’s thyroiditis), rheumatoid arthritis, and other autoimmune conditions because all of them share underlying mechanisms of chronic inflammation, immune dysfunction, and metabolic dysregulation. Treating these conditions in isolation often misses how they reinforce each other.

Does PMOS cause prediabetes or type 2 diabetes?

PMOS frequently drives insulin resistance, which is the upstream driver of prediabetes and, eventually, type 2 diabetes. Women with PMOS have a significantly elevated risk of developing type 2 diabetes if their insulin resistance is unaddressed. Early identification and treatment of insulin resistance can prevent this progression.

How is PMOS treated?

PMOS treatment addresses the upstream metabolic and hormonal dysfunction rather than just the downstream symptoms. At Vytal Health, treatment is built across four foundational levers: nutrition that supports insulin sensitivity, resistance training, sleep and stress regulation, and targeted supplementation. Medication including compounded GLP-1 therapy, spironolactone, and bioidentical hormones may be layered in strategically when indicated.

Can PMOS be reversed?

PMOS is a chronic metabolic condition that can be well-managed but not “cured” in the sense that it permanently disappears. With the right framework — proper labs, an integrated treatment plan, and ongoing physician partnership — most women can reduce their symptoms significantly or eliminate them, restore regular cycles, address fertility issues, and lower their long-term cardiometabolic risk. Maintenance requires staying inside the patterns that produced the improvement.

What does Vytal Health do differently for PMOS treatment?

Vytal Health is a telehealth practice that provides physician-led PMOS care built around comprehensive labs, the use of tools like continuous glucose monitors when clinically indicated, an integrated treatment plan addressing comorbidities, and a longitudinal relationship with the same physician across years rather than transactional one-off visits.

ABOUT THE MEDICAL REVIEWER

Dr. Alicia McCubbins, ND

Naturopathic Medicine & Functional Fertility

Dr. McCubbins is a Vytal Health physician with more than 15 years of clinical experience in naturopathic and functional medicine. Her clinical focus includes metabolic conditions, hormone optimization across all life stages, fertility and preconception care, autoimmune conditions and immune regulation, and longevity and preventive medicine — areas of expertise directly relevant to the integrated PMOS care described in this post.

She holds a Doctorate in Naturopathic Medicine from the National University of Natural Medicine and a B.S. in Dietetics from the University of Wisconsin–Madison, with honors in research on detoxification methods. Dr. McCubbins works with patients who are unwell and with those who feel well but want to perform better, age stronger, and build a healthier future.

Sources & Further Reading

Endocrine Society Press Release, May 12, 2026 — Polyendocrine Metabolic Ovarian Syndrome: New Name to Improve Diagnosis and Care
The Lancet — “The renaming of PCOS to PMOS,” May 2026 — The Lancet article
Monash Centre for Health Research & Implementation — PMOS Resources and International Guidelines

PMOS vs. PCOS: Why the Shift to a Metabolic Health Approach Matters